科技制造持续领跑，多笔亿元级别融资落地｜21投融资周报

Core Insights - The technology and manufacturing, as well as healthcare sectors, are solidifying their positions as the dual core of investment activity, with significant financing cases concentrated in these areas [1] - The past two weeks have seen a surge in financing activities, particularly in embodied intelligence, new drug development, and advanced manufacturing [1][2] Financing Overview - A total of 23 financing events were disclosed in the domestic primary market from February 9 to February 23, 2026, with a total financing scale exceeding 38.09 billion RMB [2] - The healthcare sector completed 12 financing rounds amounting to approximately 24.44 billion RMB, while the technology and manufacturing sector completed 10 rounds totaling about 12.65 billion RMB [4] Sector Distribution - The financing distribution shows that the technology and manufacturing sector had 10 cases with a disclosed amount of approximately 12.65 billion RMB, while the healthcare sector had 12 cases with about 24.44 billion RMB [4] - The consumer services sector had only 1 case with a disclosed amount of 1 billion RMB [4] Regional Distribution - The financing activities were primarily concentrated in Shanghai, Guangdong, Beijing, Jiangsu, and Zhejiang, with Shanghai leading with 8 cases [5] Active Investment Institutions - Hillhouse Capital was notably active, completing 3 financing rounds primarily in the healthcare sector [6] Notable Financing Cases - Shanghai Yuesai Biotechnology completed a new round of financing of 50 million RMB on February 11, 2026, focusing on stem cell therapy [7] - Supervision completed over 100 million RMB in B+ round financing on February 10, 2026, for advanced imaging systems [8] - Ice Crystal Intelligent completed several million RMB in A+ round financing on February 10, 2026, focusing on cardiac intervention devices [9] - Huixin Biotechnology completed nearly 100 million RMB in A+ round financing on February 10, 2026, for exosome purification and cancer early detection [10] - Regend Therapeutics completed 350 million RMB in C round financing on February 11, 2026, focusing on regenerative medicine [11] - Beijing Zhiren Medical Technology completed 300 million RMB in A+ round financing on February 11, 2026, for brain-machine interface technology [12] - KSKD completed nearly 500 million RMB in a new round of financing on February 10, 2026, focusing on original drug development [13] - AGILINK completed several hundred million RMB in A round financing on February 11, 2026, focusing on robotic end-effectors [14] - Juwei Technology completed over 100 million RMB in A+ round financing on February 11, 2026, focusing on embodied intelligence technology [15] - Baier New Materials completed 65 million RMB in B round financing on February 11, 2026, focusing on 3D printing electronic materials [16] - INFLYNC completed over 100 million RMB in A round financing on February 11, 2026, focusing on eVTOL aircraft [18] - Xinghai Map completed 1 billion RMB in B round financing on February 11, 2026, focusing on embodied intelligence services [19] - Krey Technology completed over 100 million RMB in B round financing on February 11, 2026, focusing on micro-motor production [20] - Qunche Intelligent completed several million RMB in angel round financing on February 10, 2026, focusing on embodied intelligence technology [21]